In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why The M&A Boom Many Expected In 2018 Didn’t Happen

Executive Summary

High valuations, an uncertain biopharma macro environment and widespread use of US tax reform benefits for share buybacks and capital investments resulted in less major M&A than expected. Opinions vary widely on whether 2019 will be any different.

You may also be interested in...



AstraZeneca, Novartis Continued Divestment Sprees In 2018, While Peers Joined The Action

While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.

Brii Bio: Partnering To Bring Innovation To China

Emerging Company Profile: Brii Bio has been set up in Shanghai with robust initial funding and a handful of founding partnerships to help in its goal of accelerating innovation and optimizing access to the latest medicines for Chinese patients, with a focus on treatments for chronic illnesses with significant burdens, including infectious diseases, liver and lung disorders.

'Immediate' Steps To Lower Drug Prices: The HHS Action Plan

Many of US drug pricing blueprint's proposals could be accomplished administratively, but will still be shaped by stakeholder feedback.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM009163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel